Wilkerson J - Search Results

1

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Burotto M, et al. Among authors: wilkerson j. Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3. Oncologist. 2015. PMID: 26040622 Free PMC article. Clinical Trial.

2

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

Wilkerson J, Fojo T. Wilkerson J, et al. Cancer J. 2009 Sep-Oct;15(5):379-85. doi: 10.1097/PPO.0b013e3181bef8cd. Cancer J. 2009. PMID: 19826357 Review.

3

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Burotto M, Manasanch EE, Wilkerson J, Fojo T. Burotto M, et al. Among authors: wilkerson j. Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795635 Free PMC article.

4

Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Vidaurre T, et al. Among authors: wilkerson j. Cancer J. 2009 Sep-Oct;15(5):366-73. doi: 10.1097/PPO.0b013e3181b9d37b. Cancer J. 2009. PMID: 19826355 Free PMC article. Review.

5

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE. Stein WD, et al. Among authors: wilkerson j. Clin Cancer Res. 2012 Apr 15;18(8):2374-81. doi: 10.1158/1078-0432.CCR-11-2275. Epub 2012 Feb 17. Clin Cancer Res. 2012. PMID: 22344231 Free PMC article. Clinical Trial.

6

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. O'Sullivan C, et al. Among authors: wilkerson j. J Clin Endocrinol Metab. 2014 Apr;99(4):1291-7. doi: 10.1210/jc.2013-2298. Epub 2014 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423320 Free PMC article. Clinical Trial.

7

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Burotto M, et al. Among authors: wilkerson j. PLoS One. 2014 May 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014. PLoS One. 2014. PMID: 24796484 Free PMC article. Clinical Trial.

8

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Blagoev KB, et al. Among authors: wilkerson j. Cancer Res. 2014 Sep 1;74(17):4653-62. doi: 10.1158/0008-5472.CAN-14-0420. Cancer Res. 2014. PMID: 25183789 Free PMC article.

9

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Jawed I, et al. Among authors: wilkerson j. JAMA Oncol. 2015 Sep;1(6):787-95. doi: 10.1001/jamaoncol.2015.1790. JAMA Oncol. 2015. PMID: 26181239

10

Mitosis is not a key target of microtubule agents in patient tumors.

Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Komlodi-Pasztor E, et al. Among authors: wilkerson j. Nat Rev Clin Oncol. 2011 Feb 1;8(4):244-50. doi: 10.1038/nrclinonc.2010.228. Nat Rev Clin Oncol. 2011. PMID: 21283127 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

451 results

Search Page

Filters